Aclaris Therapts (ACRS)

$2.10 +0.03 (1.45%)
Market Cap 227.50M
Revenue (ttm) 18.72M
Net Income (ttm) -132.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -705.50%
Debt to Equity Ratio 0.00
Volume 749,200
Avg Vol 1,215,264
Day's Range N/A - N/A
Shares Out 108.33M
Stochastic %K 87%
Beta 0.27
Analysts Strong Sell
Price Target $7.86

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 324 7933
Address:
701 Lee Road, Suite 103, Wayne, United States
kiboe
kiboe Sep. 6 at 2:56 AM
$ACRS price in 2027 will be at $30 lol get on board, this thing will hit $20 next year
0 · Reply
Bionco
Bionco Sep. 4 at 8:03 PM
$ACRS Great close today! That’s three straight days above the 200-day SMA and two days holding above the channel resistance. I’ll be off ST for the next 20 days—hopefully the price will give me a nice surprise when I’m back.
1 · Reply
Bionco
Bionco Sep. 4 at 2:40 PM
$ACRS do you believe there are retards who bought ACRS for a investor's conference and sold after it? It is really happening 😂
0 · Reply
Bionco
Bionco Sep. 4 at 1:52 PM
$ACRS We could see a second royalty check from Sun Pharma as early as later this year, and there’s also a chance for non-dilutive funding, like monetizing our IP, in the near term. Said Dr. Walker..
0 · Reply
Bionco
Bionco Sep. 4 at 12:05 PM
$ACRS. With Sanofi’s setback, our window of opportunity is opening. https://www.bloomberg.com/news/articles/2025-09-04/sanofi-s-new-eczema-drug-clears-key-late-stage-clinical-trial
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 11:18 AM
$ACRS Brilliant piece that captures ACRS's situation perfectly. So if you want to update your understanding of ACRS or get to know ACRS better, this is essential reading. https://beyondspx.com/quote/ACRS/aclaris-therapeutics-pipeline-catalysts-and-extended-runway-power-immuno-inflammatory-focus-nasdaq-acrs#analysis
0 · Reply
Bionco
Bionco Sep. 4 at 11:09 AM
$ACRS Sino Biopharma, the parent company of CTTQ, will present detailed results from the phase 2 trial of TQC2371 (ATI-045) in severe asthma at ERS 2025 in Amsterdam late this September. Reposted just in case some people might miss it !
1 · Reply
Stockboy1234567
Stockboy1234567 Sep. 3 at 8:36 PM
$ACRS last fall the price started to slowly trend upwards. I’m curious if this is history repeating itself.
1 · Reply
Bionco
Bionco Sep. 3 at 8:06 PM
$ACRS Second day closing above the 200-day SMA and breaking past the channel resistance too. The Breakout needs to be confirmed next few days.
2 · Reply
Btolz
Btolz Sep. 3 at 7:52 PM
$ACRS
0 · Reply
Latest News on ACRS
Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 27, 2025, 8:00 AM EDT - 11 days ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:59 AM EDT - 4 weeks ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 29, 2025, 4:01 PM EDT - 5 weeks ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Announces Leadership Transition

Jul 28, 2025, 8:45 AM EDT - 5 weeks ago

Aclaris Therapeutics Announces Leadership Transition

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 30, 2025, 9:31 AM EDT - 2 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 26, 2025, 4:01 PM EDT - 2 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Jun 23, 2025, 6:59 AM EDT - 2 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 28, 2025, 9:20 AM EDT - 3 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 9, 2025, 7:00 AM EDT - 4 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:50 AM EDT - 4 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Mar 4, 2025, 7:00 AM EST - 6 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Feb 12, 2025, 6:50 AM EST - 7 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 30, 2025, 4:01 PM EST - 7 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 6, 2025, 4:30 PM EST - 8 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Dec 23, 2024, 1:41 PM EST - 9 months ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 10 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 19, 2024, 3:27 PM EST - 10 months ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:50 AM EST - 10 months ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 10 months ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 18, 2024, 8:10 AM EST - 10 months ago

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Jan 10, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics Provides Corporate Update

Dec 19, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Provides Corporate Update

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Dec 5, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:19 AM EST - 1 year ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 13, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 28, 2023, 7:18 AM EDT - 2 years ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Jun 13, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Jun 2, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

May 8, 2023, 11:56 AM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 8, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

May 2, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

Mar 9, 2023, 7:30 AM EST - 2 years ago

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

kiboe
kiboe Sep. 6 at 2:56 AM
$ACRS price in 2027 will be at $30 lol get on board, this thing will hit $20 next year
0 · Reply
Bionco
Bionco Sep. 4 at 8:03 PM
$ACRS Great close today! That’s three straight days above the 200-day SMA and two days holding above the channel resistance. I’ll be off ST for the next 20 days—hopefully the price will give me a nice surprise when I’m back.
1 · Reply
Bionco
Bionco Sep. 4 at 2:40 PM
$ACRS do you believe there are retards who bought ACRS for a investor's conference and sold after it? It is really happening 😂
0 · Reply
Bionco
Bionco Sep. 4 at 1:52 PM
$ACRS We could see a second royalty check from Sun Pharma as early as later this year, and there’s also a chance for non-dilutive funding, like monetizing our IP, in the near term. Said Dr. Walker..
0 · Reply
Bionco
Bionco Sep. 4 at 12:05 PM
$ACRS. With Sanofi’s setback, our window of opportunity is opening. https://www.bloomberg.com/news/articles/2025-09-04/sanofi-s-new-eczema-drug-clears-key-late-stage-clinical-trial
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 11:18 AM
$ACRS Brilliant piece that captures ACRS's situation perfectly. So if you want to update your understanding of ACRS or get to know ACRS better, this is essential reading. https://beyondspx.com/quote/ACRS/aclaris-therapeutics-pipeline-catalysts-and-extended-runway-power-immuno-inflammatory-focus-nasdaq-acrs#analysis
0 · Reply
Bionco
Bionco Sep. 4 at 11:09 AM
$ACRS Sino Biopharma, the parent company of CTTQ, will present detailed results from the phase 2 trial of TQC2371 (ATI-045) in severe asthma at ERS 2025 in Amsterdam late this September. Reposted just in case some people might miss it !
1 · Reply
Stockboy1234567
Stockboy1234567 Sep. 3 at 8:36 PM
$ACRS last fall the price started to slowly trend upwards. I’m curious if this is history repeating itself.
1 · Reply
Bionco
Bionco Sep. 3 at 8:06 PM
$ACRS Second day closing above the 200-day SMA and breaking past the channel resistance too. The Breakout needs to be confirmed next few days.
2 · Reply
Btolz
Btolz Sep. 3 at 7:52 PM
$ACRS
0 · Reply
Bionco
Bionco Sep. 3 at 5:48 PM
$CTMX my three babies, $ACRS, $VTYX and $CTMX, all are and will be doing well in the long run!
1 · Reply
moneytome
moneytome Sep. 3 at 1:56 PM
$UAA looking for bounce to $6 here. $ACRS just started. $SATL looking for breakout soon
0 · Reply
Bionco
Bionco Sep. 3 at 1:41 PM
$ACRS is extremely undervalued compared to $UPB and $CRVS!
1 · Reply
Btolz
Btolz Sep. 2 at 1:58 PM
$ACRS
0 · Reply
moneytome
moneytome Sep. 2 at 1:52 PM
$ACRS should be a multi week run here. Aiming for $6+
2 · Reply
Bionco
Bionco Sep. 2 at 1:43 PM
$ACRS Breakout is happening!
0 · Reply
OK78
OK78 Aug. 31 at 7:17 PM
$ACRS Wait for 4$ in september
0 · Reply
Bionco
Bionco Aug. 29 at 8:18 PM
$ACRS I am a long term investor here!
0 · Reply
swingexpert
swingexpert Aug. 29 at 7:08 PM
$ACRS still in a trading range; a gap-up opening above the ma200-day is needed to confirm a breakout.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Aug. 29 at 5:39 PM
$ACRS $CCLD $ATYR …those that follow my pics…enjoy today’s sea of green in the sea of red 😀…BTW ACRS just starting!!!!!
0 · Reply
buymoremakemore
buymoremakemore Aug. 29 at 5:11 PM
$ACRS This is still cheap. After I get more liquidity Ill go from 50k shares to 75k shares for final position.
0 · Reply
moneytome
moneytome Aug. 29 at 4:46 PM
$ACRS next week will be fun! Enjoy the holiday ❤️
1 · Reply